Publication:
Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.

Simple item page
dc.contributor.authorPavel, Marianne
dc.contributor.authorGross, David J
dc.contributor.authorBenavent, Marta
dc.contributor.authorPerros, Petros
dc.contributor.authorSrirajaskanthan, Raj
dc.contributor.authorWarner, Richard R P
dc.contributor.authorKulke, Matthew H
dc.contributor.authorAnthony, Lowell B
dc.contributor.authorKunz, Pamela L
dc.contributor.authorHörsch, Dieter
dc.contributor.authorWeickert, Martin O
dc.contributor.authorLapuerta, Pablo
dc.contributor.authorJiang, Wenjun
dc.contributor.authorKassler-Taub, Kenneth
dc.contributor.authorWason, Suman
dc.contributor.authorFleming, Rosanna
dc.contributor.authorFleming, Douglas
dc.contributor.authorGarcia-Carbonero, Rocio
dc.date.accessioned2023-01-25T10:02:39Z
dc.date.available2023-01-25T10:02:39Z
dc.date.issued2018-01-12
dc.description.abstractTelotristat ethyl, a tryptophan hydroxylase inhibitor, was efficacious and well tolerated in the phase 3 TELESTAR study in patients with carcinoid syndrome (CS) experiencing ≥4 bowel movements per day (BMs/day) while on somatostatin analogs (SSAs). TELECAST, a phase 3 companion study, assessed the safety and efficacy of telotristat ethyl in patients with CS (diarrhea, flushing, abdominal pain, nausea or elevated urinary 5-hydroxyindoleacetic acid (u5-HIAA)) with
dc.identifier.doi10.1530/ERC-17-0455
dc.identifier.essn1479-6821
dc.identifier.pmcPMC5811631
dc.identifier.pmid29330194
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811631/pdf
dc.identifier.unpaywallURLhttps://erc.bioscientifica.com/downloadpdf/journals/erc/25/3/ERC-17-0455.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12005
dc.issue.number3
dc.journal.titleEndocrine-related cancer
dc.journal.titleabbreviationEndocr Relat Cancer
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number309-322
dc.pubmedtypeClinical Trial, Phase III
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeRandomized Controlled Trial
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject5-HIAA
dc.subjectcarcinoid syndrome
dc.subjectmetastatic neuroendocrine tumor
dc.subjectserotonin
dc.subjectsomatostatin analog
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshDiarrhea
dc.subject.meshDouble-Blind Method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshHydroxyindoleacetic Acid
dc.subject.meshMale
dc.subject.meshMalignant Carcinoid Syndrome
dc.subject.meshMiddle Aged
dc.subject.meshPhenylalanine
dc.subject.meshPyrimidines
dc.subject.meshSomatostatin
dc.subject.meshTreatment Outcome
dc.titleTelotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number25
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC5811631.pdf
Size:
505.04 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía